Structure, Function and Interactions of Tau: Particular Focus on Potential Drug Targets for the Treatment of Tauopathies

被引:5
|
作者
Borna, Hojjat [1 ]
Assadoulahei, Kasim [1 ]
Riazi, Gholamhossein [2 ]
Harchegani, Asghar Beigi [1 ]
Shahriary, Alireza [1 ]
机构
[1] Baqiyatallah Univ Med Sci, Syst Biol & Poisonings Inst, Chem Injuries Res Ctr, Tehran, Iran
[2] Univ Tehran, Inst Biochem & Biophys, Tehran, Iran
关键词
Tauopathy; tauopathy treatment; tau interaction partners; structure; function; neurodegeneration disease; MICROTUBULE-ASSOCIATED PROTEIN; CENTRAL-NERVOUS-SYSTEM; PROLYL ISOMERASE PIN1; INTRINSICALLY DISORDERED PROTEIN; ALZHEIMERS-DISEASE BRAIN; TRANSGENIC MOUSE MODEL; HEAT-SHOCK PROTEINS; IN-VITRO; PHOSPHATASE; 2A; PHOSPHORYLATED TAU;
D O I
10.2174/1871527317666180525112008
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background & Objective: Neurodegenrative diseases are among the most widespread life-threatening disorders around the world in elderly ages. The common feature of a group of neurodegenerative disorders, called tauopathies, is an accumulation of microtubule associated protein tau inside the neurons. The exact mechanism underlying tauopathies is not well-understood but several factors such as traumatic brain injuries and genetics are considered as potential risk factors. Although tau protein is well-known for its key role in stabilizing and organization of axonal microtubule network, it bears a broad range of functions including DNA protection and participation in signaling pathways. Moreover, the flexible unfolded structure of tau facilitates modification of tau by a wide range of intracellular enzymes which in turn broadens tau function and interaction spectrum. The distinctive properties of tau protein concomitant with the crucial role of tau interaction partners in the progression of neurodegeneration suggest tau and its binding partners as potential drug targets for the treatment of neurodegenerative diseases. Conclusion: This review aims to give a detailed description of structure, functions and interactions of tau protein in order to provide insight into potential therapeutic targets for treatment of tauopathies.
引用
收藏
页码:325 / 337
页数:13
相关论文
共 50 条
  • [1] Tau Oligomers as Potential Targets for Immunotherapy for Alzheimer's Disease and Tauopathies
    Lasagna-Reeves, C. A.
    Castillo-Carranza, D. L.
    Jackson, G. R.
    Kayed, R.
    CURRENT ALZHEIMER RESEARCH, 2011, 8 (06) : 659 - 665
  • [2] Tau-directed drug discovery for Alzheimer's disease and related tauopathies: A focus on tau assembly inhibitors
    Brunden, Kurt R.
    Ballatore, Carlo
    Crowe, Alex
    Smith, Amos B., III
    Lee, Virginia M-Y
    Trojanowski, John Q.
    EXPERIMENTAL NEUROLOGY, 2010, 223 (02) : 304 - 310
  • [3] Drug candidates promoting O-linked glycosylation of tau for the treatment of tauopathies
    Wiessner, C.
    Quattropani, A.
    Neny, M.
    Ousson, S.
    Hantson, J.
    Sand, A.
    Permanne, B.
    Beher, D.
    MOVEMENT DISORDERS, 2015, 30 : S430 - S430
  • [4] Amisulpride as a potential disease-modifying drug in the treatment of tauopathies
    Jahreis, Kathrin
    Bruege, Alina
    Borsdorf, Saskia
    Mueller, Franziska E.
    Sun, Weilun
    Jia, Shaobo
    Kang, Dong Min
    Boesen, Nicolette
    Shin, Seulgi
    Lim, Sungsu
    Koroleva, Anastasia
    Satala, Grzegorz
    Bojarski, Andrzej J.
    Rakusa, Elena
    Fink, Anne
    Doblhammer-Reiter, Gabriele
    Kim, Yun Kyung
    Dityatev, Alexander
    Ponimaskin, Evgeni
    Labus, Josephine
    ALZHEIMERS & DEMENTIA, 2023, 19 (12) : 5482 - 5497
  • [5] Function and regulation of cis P-tau in the pathogenesis and treatment of conventional and nonconventional tauopathies
    Wang, Ruizhi
    Lu, Kun Ping
    Zhou, Xiao Zhen
    JOURNAL OF NEUROCHEMISTRY, 2023, 166 (06) : 904 - 914
  • [6] Treatment of the metabolic disturbances caused by antipsychotic drugs - Focus on potential drug interactions
    Baptista, T
    Kin, NMKNY
    Beaulieu, S
    CLINICAL PHARMACOKINETICS, 2004, 43 (01) : 1 - 15
  • [7] Potential drug targets and treatment of schizophrenia
    Kumar, Anil
    Yadav, Monu
    Parle, Milind
    Dhingra, Sameer
    Dhull, Dinesh K.
    INFLAMMOPHARMACOLOGY, 2017, 25 (03) : 277 - 292
  • [8] Potential drug targets and treatment of schizophrenia
    Anil Kumar
    Monu Yadav
    Milind Parle
    Sameer Dhingra
    Dinesh K. Dhull
    Inflammopharmacology, 2017, 25 : 277 - 292
  • [9] Whole CNS Human Tau Knockdown for the Potential Treatment of Alzheimer's Disease and Other Tauopathies
    Zeitler, Bryan J.
    Marlen, Kimberly
    Ojala, David
    Ledeboer, Annemarie
    Yu, Qi
    Pan, Yonghua
    Cisbani, Giulia
    Peters, Finn
    Melis, Chiara
    Tiffany, Matthew R.
    Mueller, Sarah
    Kennard, Kenneth
    Dunn, Patrick
    Hoang-Oanh Nguyen
    Hung Tran
    Meyer, Kathleen
    Pooler, Amy
    MOLECULAR THERAPY, 2024, 32 (04) : 535 - 535